Journal articles on the topic 'Melanoma, BRAF, target therapy, melanoma acrale'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Melanoma, BRAF, target therapy, melanoma acrale.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Gams, Polona, Zvezdana Dolenc Stražar, Maja Šoštarič, Matic Bošnjak, and Juš Kšela. "Cardiac Melanoma Metastasis with ERBB2 Gene Amplification: A Potential for Future Targeted Therapy." Case Reports in Oncology 14, no. 1 (March 29, 2021): 622–27. http://dx.doi.org/10.1159/000514981.
Full textTsai, Katy K., Iwei Yeh, Adil Daud, and Ari Oglesby. "Phase II study of binimetinib with imatinib in patients with unresectable KIT-mutant melanoma." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): TPS9594. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps9594.
Full textYeh, Iwei, Eric Jorgenson, Ling Shen, Mengshu Xu, Jeffrey P. North, A. Hunter Shain, David Reuss, et al. "Targeted Genomic Profiling of Acral Melanoma." JNCI: Journal of the National Cancer Institute 111, no. 10 (January 18, 2019): 1068–77. http://dx.doi.org/10.1093/jnci/djz005.
Full textTeixido, Cristina, Paola Castillo, Clara Martinez-Vila, Ana Arance, and Llucia Alos. "Molecular Markers and Targets in Melanoma." Cells 10, no. 9 (September 5, 2021): 2320. http://dx.doi.org/10.3390/cells10092320.
Full textRodrigues, Ana Sofia, and Ana Brinca. "Treatment of BRAF-Mutated Metastatic Melanoma: Immunotherapy or Target Therapy?" Journal of the Portuguese Society of Dermatology and Venereology 79, no. 2 (June 25, 2021): 103–11. http://dx.doi.org/10.29021/spdv.79.2.1342.
Full textJebali, Ahlem, Maxime Battistella, Céleste Lebbé, and Nicolas Dumaz. "RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy." Biomedicines 9, no. 10 (October 19, 2021): 1498. http://dx.doi.org/10.3390/biomedicines9101498.
Full textFattore, Luigi, Rita Mancini, Mario Acunzo, Giulia Romano, Alessandro Laganà, Maria Elena Pisanu, Debora Malpicci, et al. "miR-579-3p controls melanoma progression and resistance to target therapy." Proceedings of the National Academy of Sciences 113, no. 34 (August 8, 2016): E5005—E5013. http://dx.doi.org/10.1073/pnas.1607753113.
Full textPizzimenti, Stefania, Simone Ribero, Marie Angele Cucci, Margherita Grattarola, Chiara Monge, Chiara Dianzani, Giuseppina Barrera, and Giuliana Muzio. "Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies." Antioxidants 10, no. 12 (December 3, 2021): 1942. http://dx.doi.org/10.3390/antiox10121942.
Full textRossi, Ernesto, Giovanni Schinzari, Francesco Cellini, Mario Balducci, Mariangela Pasqualoni, Brigida Anna Maiorano, Bruno Fionda, et al. "Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma." Biomedicines 11, no. 2 (January 29, 2023): 394. http://dx.doi.org/10.3390/biomedicines11020394.
Full textPavlick, Anna C., Leslie Fecher, Paolo A. Ascierto, and Ryan J. Sullivan. "Frontline Therapy forBRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?" American Society of Clinical Oncology Educational Book, no. 39 (May 2019): 564–71. http://dx.doi.org/10.1200/edbk_243071.
Full textIce, Ryan J., Michelle Chen, Max Sidorov, Tam Le Ho, Rinette W. L. Woo, Aida Rodriguez-Brotons, Tri Luu, et al. "Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies." British Journal of Cancer 122, no. 5 (December 20, 2019): 648–57. http://dx.doi.org/10.1038/s41416-019-0696-y.
Full textAndronova, N. V., L. F. Morozova, I. N. Mikhailova, A. A. Lushnikova, D. A. Ponkratova, N. T. Raychlin, I. A. Bukaeva, U. A. Borisova, S. M. Sitdikova, and H. M. Treshalina. "MODELING OF A SUBCUTANEOUS XENOGRAFT OF HUMAN SKIN MELANOMA MEL CHER WITH V600E BRAF MUTATION IN IMMUNODEFICIENT MICE FOR PRECLINICAL STUDY THE TARGETING ANTICANCER DRUGS." Russian Journal of Biotherapy 15, no. 4 (December 30, 2016): 65–71. http://dx.doi.org/10.17650/1726-9784-2016-15-4-65-71.
Full textMoiseyenko, Fedor V., Vitaliy V. Egorenkov, Mikhail M. Kramchaninov, Elizaveta V. Artemieva, Svetlana N. Aleksakhina, Maxim M. Holmatov, Vladimir M. Moiseyenko, and Evgeny N. Imyanitov. "Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation." Case Reports in Oncology 12, no. 2 (May 16, 2019): 339–43. http://dx.doi.org/10.1159/000500481.
Full textPorumb-Andrese, Elena, Ramona Gabriela Ursu, Iuliu Ivanov, Irina-Draga Caruntu, Vlad Porumb, Dan Ferariu, Costin Damian, Delia Ciobanu, Cristina Terinte, and Luminita Smaranda Iancu. "The BRAF V600E Mutation Detection by quasa Sensitive Real-Time PCR Assay in Northeast Romania Melanoma Patients." Applied Sciences 11, no. 20 (October 13, 2021): 9511. http://dx.doi.org/10.3390/app11209511.
Full textMcKenna, Stephanie, and Lucía García-Gutiérrez. "Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?" International Journal of Molecular Sciences 22, no. 10 (May 12, 2021): 5115. http://dx.doi.org/10.3390/ijms22105115.
Full textHu-Lieskovan, Siwen, Lidia Robert, Blanca Homet Moreno, and Antoni Ribas. "Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges." Journal of Clinical Oncology 32, no. 21 (July 20, 2014): 2248–54. http://dx.doi.org/10.1200/jco.2013.52.1377.
Full textTímár, József, and Andrea Ladányi. "Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction." International Journal of Molecular Sciences 23, no. 10 (May 11, 2022): 5384. http://dx.doi.org/10.3390/ijms23105384.
Full textYilmaz, Mesut, and Şermin Güven Meşe. "Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma." Journal of Oncology Pharmacy Practice 26, no. 7 (March 29, 2020): 1754–58. http://dx.doi.org/10.1177/1078155220906011.
Full textRuggiero, Ciro Francesco, Debora Malpicci, Luigi Fattore, Gabriele Madonna, Vito Vanella, Domenico Mallardo, Domenico Liguoro, et al. "ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin." Cancers 11, no. 10 (September 25, 2019): 1425. http://dx.doi.org/10.3390/cancers11101425.
Full textLau, Peter Kar Han, Carleen Cullinane, Susan Jackson, Rachael Walker, Lorey K. Smith, Alison Slater, Laura Kirby, et al. "Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma." Cancers 13, no. 24 (December 17, 2021): 6342. http://dx.doi.org/10.3390/cancers13246342.
Full textBecco, Paolo, Susanna Gallo, Stefano Poletto, Mirko Pio Manlio Frascione, Luca Crotto, Alessandro Zaccagna, Luca Paruzzo, Daniela Caravelli, Fabrizio Carnevale-Schianca, and Massimo Aglietta. "Melanoma Brain Metastases in the Era of Target Therapies: An Overview." Cancers 12, no. 6 (June 21, 2020): 1640. http://dx.doi.org/10.3390/cancers12061640.
Full textKarki, Prashant, Shayne Sensenbach, Vahideh Angardi, and Mehmet A. Orman. "BRAF-Inhibitor-Induced Metabolic Alterations in A375 Melanoma Cells." Metabolites 11, no. 11 (November 14, 2021): 777. http://dx.doi.org/10.3390/metabo11110777.
Full textNepote, Alessandro, Gianluca Avallone, Simone Ribero, Francesco Cavallo, Gabriele Roccuzzo, Luca Mastorino, Claudio Conforti, et al. "Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma." Journal of Clinical Medicine 11, no. 3 (February 4, 2022): 828. http://dx.doi.org/10.3390/jcm11030828.
Full textTestori, Alessandro A. E., Silvia Chiellino, and Alexander C. J. van Akkooi. "Adjuvant Therapy for Melanoma: Past, Current, and Future Developments." Cancers 12, no. 7 (July 21, 2020): 1994. http://dx.doi.org/10.3390/cancers12071994.
Full textFattore, Luigi, Virginia Campani, Ciro Francesco Ruggiero, Valentina Salvati, Domenico Liguoro, Lorena Scotti, Gerardo Botti, et al. "In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma." International Journal of Molecular Sciences 21, no. 6 (March 12, 2020): 1930. http://dx.doi.org/10.3390/ijms21061930.
Full textValpione, Sara, Luca G. Campana, Jacopo Pigozzo, and Vanna Chiarion-Sileni. "Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib." Radiology and Oncology 49, no. 1 (March 1, 2015): 71–74. http://dx.doi.org/10.2478/raon-2014-0035.
Full textSarnaik, Amod, Sajeve Samuel Thomas, Diwakar Davar, John M. Kirkwood, Harriet M. Kluger, Jose Lutzky, Melissa Wilson, et al. "Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy." Journal of Clinical Oncology 37, no. 8_suppl (March 10, 2019): 136. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.136.
Full textSarnaik, Amod, Nikhil I. Khushalani, Jason Alan Chesney, Harriet M. Kluger, Brendan D. Curti, Karl D. Lewis, Sajeve Samuel Thomas, et al. "Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 2518. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2518.
Full textDzienis, Marcin Radoslaw, and Victoria Atkinson. "Response rate to vemurafenib in BRAF-positive melanoma brain metastases." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 9081. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9081.
Full textAlgazi, Alain Patrick, Christian Posch, Susana Ortiz-Urda, Alyson Cockerill, Pamela N. Munster, and Adil Daud. "BKM120 combined with vemurafenib in vemurafenib-refractory BRAF mutant metastatic melanoma: Two cases." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e20010-e20010. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e20010.
Full textBernocchi, Ottavia, Marianna Sirico, Silvia Paola Corona, Carla Strina, Manuela Milani, Maria Rosa Cappelletti, Giuseppina Ferrero, et al. "Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature." Pharmaceuticals 14, no. 2 (February 16, 2021): 159. http://dx.doi.org/10.3390/ph14020159.
Full textHomicsko, Krisztian Gyuta, Veronica Aedo, Edoardo Missiaglia, Bettina Bisig, and Olivier Michielin. "Targeting MAP2K1 mutation with trametinib in a triple wild-type melanoma patient." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e21027-e21027. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e21027.
Full textFattore, Luigi, Rita Mancini, and Gennaro Ciliberto. "Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma." Cancers 12, no. 11 (November 13, 2020): 3368. http://dx.doi.org/10.3390/cancers12113368.
Full textJamme, Philippe, Guillaume Delzenne, Laurent Mortier, Olivier Farchi, and Marie Boileau. "Relevance of detection of RAF fusion in pan-negative melanoma in routine practice." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e21500-e21500. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21500.
Full textTawbi, Hussein A., Celine Boutros, David Kok, Caroline Robert, and Grant McArthur. "New Era in the Management of Melanoma Brain Metastases." American Society of Clinical Oncology Educational Book, no. 38 (May 2018): 741–50. http://dx.doi.org/10.1200/edbk_200819.
Full textRager, Taylor, Adam Eckburg, Meet Patel, Rong Qiu, Shahina Gantiwala, Katrina Dovalovsky, Kelly Fan, et al. "Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies." Cancers 14, no. 15 (August 3, 2022): 3779. http://dx.doi.org/10.3390/cancers14153779.
Full textComunanza, Valentina, Chiara Gigliotti, Gabriella Doronzo, Valentina Martin, Anna Gattuso, Dario Sangiolo, Federica Di Nicolantonio, and Federico Bussolino. "Abstract B17: VEGF removal delays the onset of acquired resistance to target therapy and increases the efficacy of immune checkpoint inhibitors in BRAF-mutated melanoma." Cancer Research 80, no. 19_Supplement (October 1, 2020): B17. http://dx.doi.org/10.1158/1538-7445.mel2019-b17.
Full textMusi, Alice, and Laura Bongiovanni. "Extracellular Vesicles in Cancer Drug Resistance: Implications on Melanoma Therapy." Cancers 15, no. 4 (February 8, 2023): 1074. http://dx.doi.org/10.3390/cancers15041074.
Full textSosman, Jeffrey A. "Abstract IA24: Are there nonimmune targets in the BRAFV600 WT melanoma patient?" Cancer Research 80, no. 19_Supplement (October 1, 2020): IA24. http://dx.doi.org/10.1158/1538-7445.mel2019-ia24.
Full textGatalica, Zoran, Kathleen D. Danenberg, Matthew Jerome McGinniss, Anatole Ghazalpour, Ryan P. Bender, Raheela Ashfaq, David Arguello, Brian Wright, Nicole Griffin, and Gargi D. Basu. "Molecular profiling of uveal melanoma patients." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 10630. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10630.
Full textMikhaylova, I. N., E. M. Treshalina, L. F. Morozova, N. V. Andronova, I. Zh Shubina, and A. A. Lushnikova. "Cell lines of human melanoma and their xenograft with braf or nras mutations a targets for targeted therapy. Reviews." Russian Journal of Biotherapy 17, no. 4 (January 11, 2019): 27–35. http://dx.doi.org/10.17650/1726-9784-2018-17-4-27-35.
Full textSarnaik, Amod, Nikhil Khushalani, Jason Chesney, Harriet Kluger, Brendan Curti, Karl Lewis, Theresa Medina, et al. "P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update." Journal for ImmunoTherapy of Cancer 8, Suppl 1 (April 2020): A12. http://dx.doi.org/10.1136/lba2019.18.
Full textKendra, Kari Lynn, Ryan Watson, and Gregory B. Lesinski. "Selinexor, a selective inhibitor of nuclear export (SINE), in patients with unresectable melanoma." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e21014-e21014. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e21014.
Full textSarnaik, Amod, Nikhil I. Khushalani, Jason Alan Chesney, Karl D. Lewis, Theresa Michelle Medina, Harriet M. Kluger, Sajeve Samuel Thomas, et al. "Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 10006. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.10006.
Full textRebecca, Vito W., Jianglan Liu, Thomas Connelly, Keith Flaherty, Ze’ev Ronai, and Meenhard Herlyn. "Abstract PR18: Comparative screening of skin-derived NCSCs, melanocytes, and melanoma developmental programs reveals LPAR1 in MAPKi resistance." Cancer Research 80, no. 19_Supplement (October 1, 2020): PR18. http://dx.doi.org/10.1158/1538-7445.mel2019-pr18.
Full textBetoff, Allison, Jonathan Zippin, Taha Merghoub, Paul B. Chapman, and Jedd Wolchok. "Abstract IA10: Targeting melanoma metabolism to overcome resistance to treatment." Cancer Research 80, no. 19_Supplement (October 1, 2020): IA10. http://dx.doi.org/10.1158/1538-7445.mel2019-ia10.
Full textZhai, Zili, Prasanna K. Vaddi, Jenny Mae Samson, Tomoya Takegami, and Mayumi Fujita. "NLRP1 Functions Downstream of the MAPK/ERK Signaling via ATF4 and Contributes to Acquired Targeted Therapy Resistance in Human Metastatic Melanoma." Pharmaceuticals 14, no. 1 (December 30, 2020): 23. http://dx.doi.org/10.3390/ph14010023.
Full textMadhusudanannair, Vinu, Filip Janku, Gerald Steven Falchook, David S. Hong, Jennifer J. Wheler, Aung Naing, Siqing Fu, et al. "NRAS mutations in patients with advanced cancers treated with target-based therapies in early-phase clinical trials." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 3106. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3106.
Full textWagenseller, Aubrey G., Amber L. Shada, Kevin D'Auria, Cheryl F. Murphy, Dandan Sun, Kerrington R. Molhoek, Jason A. Papin, Anindya Dutta, and Craig L. Slingluff. "MicroRNAs induced in melanoma treated with combination targeted therapy of temsirolimus and bevacizumab." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 8597. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8597.
Full textVosganian, Gregory S., Rinke Bos, and Linda Sherman. "Immunologic Effects of An Oral BRAF Inhibitor in a BRAF Wild-Type Murine Model." Blood 118, no. 21 (November 18, 2011): 4935. http://dx.doi.org/10.1182/blood.v118.21.4935.4935.
Full text